Better Sex, Better Hair, Better Sleep: ‘Humanmaxxing’ Is Here - New York Times https://www.nytimes.com/2026/06/11/opinion/biotech-maxxing-christian-angermayer.html The biotech billionaire who wants to rebuild your body and blow your mind.
$PSIL ETF show the three biggest holdings as $DFTX $CMPS $ATAI Others will succeed too, but these three are the unicorns in the psychedelic biotech space and I suspect they will reach a combined market cap of 80-100B by H2 2027. Currently they sit at 10B combined. That is a 8-10X from these levels.
Bipartisan Congressional Bill Would Codify Trump’s Psychedelics Order Into Law https://www.marijuanamoment.net/bip...ld-codify-trumps-psychedelics-order-into-law/ H.R.9559 - To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes. https://www.congress.gov/bill/119th-congress/house-bill/9559 Helps with DEA rescheduling visibility, manufacturing quotas, controlled distribution, clinical site expansion, VA-related treatment pathways, and broader institutional comfort around psychedelic medicine. This is also the kind of policy shift that big pharma pays attention to. A late-stage drug with strong data is one thing. A late-stage drug with improving federal policy, potential priority voucher support, and clearer post-approval scheduling rules is much easier to underwrite. Bullish for the whole sector.
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder July 6, 2026 https://ir.ataibeckley.com/news-rel...-last-patient-vls-01-phase-2b-trd-study-plans 156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized anxiety disorder (GAD) as a potential follow-on indication VLS-01 and BPL-003 (in Phase 3 development for treatment-resistant depression with Breakthrough Therapy Designation) together positioned to address patients across the spectrum of mood and anxiety disorders
FDA sets public hearing on psychedelics for September 14 https://www.investing.com/news/stoc...s-fda-willing-to-move-on-comp360-93CH-4789025
HHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veterans https://www.hhs.gov/press-room/hhs-va-partner-advance-psychedelic-therapies-veterans.html
Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed https://www.biospace.com/fda/final-...fda-is-receptive-to-helping-companies-succeed
Bloomberg reports that Eli Lilly is in talks to acquire AtaiBeckley and that a deal could be announced as soon as this week. Reuters independently carried the Bloomberg report on July 15, 2026. https://www.reuters.com/business/he...gmaker-ataibeckley-bloomberg-news-2026-07-15/
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction https://www.cnbc.com/2026/07/16/eli-lilly-to-buy-psychedelics-maker-ataibeckley-2point8-billion.html
It looks like to me that what Libby did just capped profits for shareholders. Instead of continuing to climb to $10, $15, maybe $25 or $40 a share, the path to more than -$8 or $9 /share for the private investors looks unlikely, if not impossible. Since they are probably just going to fold it into Libby and not maintain it as a subsidiary with a separate ticker symbol. Those who bought enough at $2 to $5 a share will still do well. I purchased at $5/share, but not enough to make a splash. So, the lesson for big pharma is: buy out the smaller companies that are going to be successful sooner rather than later, and cut out the early shareholders.
